戈舍瑞林联合芳香化酶抑制剂治疗 转移性乳腺癌的研究

Curative effect of Goserelin combined with aromatase inhibitor in treatment of metastatic breast cancer

摘要:

目的 探究戈舍瑞林联合芳香化酶抑制剂治疗转移性乳腺癌的疗效。方法 选取2011 年1 月- 2013 年1 月于海南省人民医院收治的102 例转移性乳腺癌患者，随机分为对照组和研究组各51 例，对照组 采用常规治疗，研究组使用戈舍瑞林联合芳香化酶抑制剂，比较两组临床疗效、不良反应发生率及生存率。 结果 两组患者临床疗效比较有差异（P <0.05），研究组客观缓解率、临床获益率高于对照组（P <0.05）；研 究组2、3 年生存率高于对照组（P <0.05），研究组不良反应发生率低于对照组（P <0.05）。结论 戈舍瑞林 联合芳香化酶抑制剂治疗转移性乳腺癌疗效显著，在临床上具有推广价值。

Abstract:

Objective To explore the long-term and short-term effects of Goserelin combined with the aromatase inhibitor in the treatment of metastatic breast cancer. Methods One hundred and two cases of patients with metastatic breast cancer in our hospital from January 2011 to January 2013 were selected as the reasearch subjects and randomly divided into control group and study group, with 51 cases in each group. The control group was given conventional treatment, and the study group was given Goserelin combined with the aromatase inhibitor. The clinical effect, incidence of adverse reactions and survival rate in the two groups were analyzed. Results The difference in clinical effect between the two groups was statistically significant (P < 0.05). The objective remission rate and the clinical benefit rate in the study group were significantly higher than those in the control group (P < 0.05). The 2-year and 3-year survival rates in the study group were significantly higher than those in the control group (P < 0.05). The incidence of adverse reactions in the study group was significantly lower than that in the control group (P < 0.05). Conclusions The long-term and short-term effects of Goserelin combined with the aromatase inhibitor are significant in the treatment of metastatic breast cancer, and the therapeutic method has clinical application and promotion value.